However, concerns regarding the safety of such agents, in particular the increased risk of diabetic ketoacidosis (DKA) with SGLT2is, have restricted their widespread adoption in type 1 diabetes [15]
It works by mimicking a hormone called glucagon-like peptide-1, or GLP-1, which stimulates the bodys production of insulin
This is an important rate-limiting step in our ability to provide one specific therapy, viz., ECMO, which, for a significant number of young people in the extreme manifestation of the disease, is possibly the difference between life and death
It is about having sufficient understanding to make better clinical decisions, provide more meaningful patient education, and recognize when something does not quite add up in the examination room